0001209191-19-009041.txt : 20190211
0001209191-19-009041.hdr.sgml : 20190211
20190211173701
ACCESSION NUMBER: 0001209191-19-009041
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190207
FILED AS OF DATE: 20190211
DATE AS OF CHANGE: 20190211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Davidson Matt
CENTRAL INDEX KEY: 0001741937
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38529
FILM NUMBER: 19586745
MAIL ADDRESS:
STREET 1: C/O VERRICA PHARMACEUTICALS INC.
STREET 2: 10 NORTH HIGH STREET, SUITE 200
CITY: WEST CHESTER
STATE: PA
ZIP: 19380
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verrica Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001660334
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463137900
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 NORTH HIGH STREET
STREET 2: SUITE 200
CITY: WEST CHESTER
STATE: PA
ZIP: 19380
BUSINESS PHONE: 484-453-3300
MAIL ADDRESS:
STREET 1: 10 NORTH HIGH STREET
STREET 2: SUITE 200
CITY: WEST CHESTER
STATE: PA
ZIP: 19380
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-07
0
0001660334
Verrica Pharmaceuticals Inc.
VRCA
0001741937
Davidson Matt
C/O VERRICA PHARMACEUTICALS INC.
10 NORTH HIGH STREET, SUITE 200
WEST CHESTER
PA
19380
0
0
1
0
Common Stock
2019-02-07
4
S
0
4289
13.26
D
2975341
D
Common Stock
2019-02-08
4
S
0
700
12.86
D
2974641
D
Common Stock
2019-02-08
4
S
0
4268
13.88
D
2970373
D
Common Stock
2019-02-11
4
S
0
1800
13.19
D
2968573
D
Common Stock
2019-02-11
4
S
0
2000
13.91
D
2966573
D
These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.81 to $13.585, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.50 to $13.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $13.50 to $14.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.82 to $13.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $13.82 to $14.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Mark Ballantyne, Attorney-in-Fact
2019-02-11